Skip to main content


A Phase 1 clinical trial for adults with FLT3 mutant Acute Leukemia

What is the NCT number for COVALENT-103?

The National Clinical Trial reference number is: NCT05918692 

When you talk with your doctor or clinical trial team member, please have the national trial reference number available. 

What does it mean it is open label, non-randomized?

It means all patients will receive the BMF500, the study drug and that the dose level will be pre-allocated. There will be no placebo and the allocation will not be based on chance. 

Will it cost me anything?

Study medication and study-related care will be provided at no cost. 

18 years & over
Female & Male
R/R Leukemia with FLT3 mutations
  • Have not had success with standard of care treatments; refractory
  • Had cancer come back or get worse after getting better; relapsed
  • Adequate liver and renal function
  • Arm A: No CYP3A4 inhibitor for at least 7 days prior to enrollment
  • Arm B: Must have received azole antifungals that are moderate or strong CYP3A4 inhibitor for at least 7 days prior to enrollment

What is BMF-500?

BMF-500 is an investigational, novel, orally bioavailable, highly potent and selective covalent small molecule inhibitor of FLT3. BMF-500 was designed to have a therapeutic profile to allow for combinations with standard of care and/or novel targeted agents like BMF-219. 

Our clinical trials team will contact you shortly after your form submission.